Daratumumab, bortezomib, lenalidomide, and dexamethasone for transplant-eligible elderly patients with newly diagnosed multiple myeloma (KMM2101 trial)

Evidence supporting daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) in transplant-eligible patients aged 65–69 years with newly diagnosed multiple myeloma (NDMM) remains limited, particularly among Asian patients. Furthermore, the efficacy of six cycles of D-VRd induction before autologous stem cell transplantation (ASCT) has not been prospectively evaluated. In this multicenter, single-arm, phase II study, 26 transplant-eligible patients aged 65–69 years with NDMM received six cycles of D-VRd induction followed by ASCT. Maintenance therapy consisted of daratumumab plus lenalidomide for 12 months, followed by daratumumab monotherapy for another 12 months. The primary endpoint was the rate of very good partial response (VGPR) or better after ASCT. All patients completed induction, and 25 (96.2%) underwent ASCT. The VGPR or better rate after ASCT was 96.2%. The MRD-negative rate was 92.3%, and 65.4% achieved sustained MRD negativity for 12 months. After a median follow-up of 42.5 months, 3-year progression-free and overall survival rates were 76.9% and 88.5%, respectively. Grade ≥ 3 neutropenia was the most common adverse event, while dose intensity was generally maintained. Six cycles of D-VRd induction followed by ASCT and fixed-duration daratumumab-based maintenance achieved deep and durable responses with manageable toxicity in fit, transplant-eligible patients aged 65–69 years.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11564640/v1
Primary Topic
Multiple Myeloma Research and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Daratumumab, bortezomib, lenalidomide, and dexamethasone for transplant-eligible elderly patients with newly diagnosed multiple myeloma (KMM2101 trial)

Ja Min Byun, Wonhyoung Seo, Ho‐Young Yhim, Sungwoo Park et al.
Research Square
Multiple Myeloma Research and Treatments
preprint

Daratumumab, bortezomib, lenalidomide, and dexamethasone for transplant-eligible elderly patients with newly diagnosed multiple myeloma (KMM2101 trial)

Ja Min Byun, Wonhyoung Seo, Ho‐Young Yhim, Sungwoo Park, Ho sup Lee, Youngil Koh, Jun Ho Yi, Kihyun Kım, Hyun‐Young Kim, Sung‐Soo Park, Jung Sung-Hoon, Jae‐Yong Kwak, Chang‐Ki Min, Je‐Jung Lee, Myung-Won Lee, Sang Eun Yoon, Gyeong-Won Lee
preprint en

Abstract

Evidence supporting daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) in transplant-eligible patients aged 65–69 years with newly diagnosed multiple myeloma (NDMM) remains limited, particularly among Asian patients. Furthermore, the efficacy of six cycles of D-VRd induction before autologous stem cell transplantation (ASCT) has not been prospectively evaluated. In this multicenter, single-arm, phase II study, 26 transplant-eligible patients aged 65–69 years with NDMM received six cycles of D-VRd induction followed by ASCT. Maintenance therapy consisted of daratumumab plus lenalidomide for 12 months, followed by daratumumab monotherapy for another 12 months. The primary endpoint was the rate of very good partial response (VGPR) or better after ASCT. All patients completed induction, and 25 (96.2%) underwent ASCT. The VGPR or better rate after ASCT was 96.2%. The MRD-negative rate was 92.3%, and 65.4% achieved sustained MRD negativity for 12 months. After a median follow-up of 42.5 months, 3-year progression-free and overall survival rates were 76.9% and 88.5%, respectively. Grade ≥ 3 neutropenia was the most common adverse event, while dose intensity was generally maintained. Six cycles of D-VRd induction followed by ASCT and fixed-duration daratumumab-based maintenance achieved deep and durable responses with manageable toxicity in fit, transplant-eligible patients aged 65–69 years.

Research Square
Gyeongsang National University (KR), Chungnam National University (KR), Kosin University Gospel Hospital (KR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Gyeongsang National University Hospital (KR), Chungnam National University Hospital (KR), Chonnam National University Hwasun Hospital (KR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Jeonbuk National University (KR), Sungkyunkwan University (KR), Catholic University of Korea (KR)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon